Expert Interview
Reviewing the potential of Algernon Pharmaceutical's experimental lung disease drug, ifenprodil, for patients with IPF
Ticker(s): AGNPF, RHHBY, Boehringer IngelheimInstitution: National Jewish Health
- Associate Professor in the Department of Medicine and Clinic Director of the Interstitial lung disease(ILD) Program at National Jewish Health.
- Sub-investigator for the Phase II study for PLN 74809 as well as numerous other ILD/IPF studies being conducted at National Jewish Health.
- Research focuses on biomarkers in ILD and exercise limitation in post-COVID syndrome, with past research focused on investigating the role of angiogenesis in resolving lung injury and fibrosis.
Describe your background and practice setting
Added By: ben_adminHow many patients with IPF do you currently manage?
Added By: ben_adminWhat is your current standard of care for IPF?
Added By: ben_adminWhat are your thoughts on the data to date on ifenprodil?
Added By: ben_adminIs chronic cough a frequent issue for patients with IPF? Does ifenprodil appear to address this issue?
Added By: ben_adminHow do ifenprodil outcomes compare to the standard of care outcomes?
Added By: ben_adminCan you rank ifenprodil on a scale of 1-10?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
